explore -WSS

explore

author：explore 2025-09-29 09:55:08 - browse：72

Adam's take main illustration — Molly Ferguson/STAT

The approval Friday of Bluebird Bio’s gene therapy for sickle cell disease should have been a momentum-swinging achievement for the long-struggling biotech. Instead, the company mispriced its new drug and fumbled a pivotal financial lifeline.

The consequences of these strategic blunders — arguably, self-inflicted — could imperil Bluebird’s independence, perhaps even its survival.

Bluebird priced Lyfgenia at $3.1 million, while Vertex Pharmaceutical set the cost of Casgevy, its competing sickle cell treatment also approved on Friday, at $2.2 million. Not only is Lyfgenia significantly more expensive, but its prescribing label carries a “black box” safety warning, which requires patients undergo regular blood monitoring for cancer risk. Casgevy has no similar monitoring requirement.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Why a market frenzy over new weight loss drugs defies logic

WSS

Johnson & Johnson sues to stop Medicare negotiation

UK homeowners get some respite as inflation falls by more than anticipated to a 15

Health tech investors get more selective as pandemic boom fades

Readout LOUD podcast: Live from the 2023 STAT Summit

Roche acquires Telavant from Roivant, adding experimental IBD treatment

Questions loom on AstraZeneca cancer drug as safety concerns ebb

focus

explore

focus

Medical leaders decry Supreme Court decision on affirmative action

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

As demand for Covid shots wanes, Moderna seeks its next success

Roivant's CEO is a star, but biotech's black hole persists

Cancer drug shortages should be causing more outrage

DeSantis says Trump could've 'come out more forcefully' during Jan. 6

Guidelines to prevent youth baseball injuries need more muscle

Smaller biotechs seek to piggyback on weight loss drug boom

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Ford plant in Missouri shuts down over 'possible threat,' sheriff's office says

explore

UnitedHealth, Optum discontinue NaviHealth name

Roivant's CEO is a star, but biotech's black hole persists

Asa Hutchinson previews new plan to reform federal law enforcement if elected in 2024

STAT Summit: How researchers deal with rejection

STAT Readout: Friday, Oct. 20 biotech updates

15 die by electrocution after transformer explodes in northern India

entertainment

focus

entertainment

knowledge